Health Insurance & Pharmacy Benefits Mgrs
SB 142 would extend Alaska insurance law requirements to certain municipal and state group health plans, including self-insured plans, and to the pharmacy benefit managers that administer those plans. For municipalities, the bill provides that if a municipality offers a group health care insurance plan for municipal employees, the plan and its pharmacy benefits manager would be subject to specified Alaska insurance provisions governing pharmacy benefit management and related unfair trade practices, unless the plan is governed by ERISA. The bill applies to both home rule and general law municipalities.
For state employee coverage, the bill amends existing statutes governing the Department of Administration’s authority to procure group insurance and to operate self-insured plans. It adds explicit language making non-ERISA state self-insured group health plans and their pharmacy benefits managers subject to the same pharmacy-benefit-management requirements. The bill also preserves existing authority for the state to offer group insurance, self-insurance, excess loss insurance, and optional coverage for certain retirees and dependents, while clarifying that pharmacy benefit administration in those plans must comply with the referenced state insurance statutes. The bill would take effect January 1, 2026.
SB 142 would amend AS 29.20, AS 39.30.090, and AS 39.30.091 to bring municipal employee health plans and state employee self-insured health plans under Alaska’s pharmacy benefit manager oversight provisions, specifically AS 21.27.901 - 21.27.975 and AS 21.36.520, except where federal ERISA preemption applies. In practical terms, this would expand state regulatory authority over how pharmacy benefits are administered in public-sector health plans and could affect plan contracting, pricing, rebates, and administrative practices for municipalities, the Department of Administration, insurers, third-party administrators, and PBMs.
No committee transcripts or recorded votes were provided, so there is no direct evidence of support or opposition from hearings or floor action. Based on the bill’s caption and text, the measure appears to be a regulatory oversight bill focused on public employee health coverage and pharmacy benefit management rather than a broad benefit expansion or cut. The absence of recorded debate in the provided materials means sentiment cannot be measured from legislative discussion, but the bill’s structure suggests a technical policy effort to align public plans with existing state PBM rules.
The main likely point of contention is the bill’s extension of state pharmacy-benefit-management requirements to municipal and state health plans, which could be viewed by municipalities, plan administrators, or PBMs as an increase in regulation and compliance burden. Another potential issue is the ERISA carveout, since the bill expressly excludes plans subject to federal ERISA, which may raise questions about which public plans are covered and how the state’s authority interacts with federal law. Because the bill affects self-insured plans and pharmacy benefit administration, stakeholders concerned about cost, contracting flexibility, and local control would be the most likely sources of opposition, while supporters would likely emphasize transparency and oversight.